Fluver^®

Fluver is the preparation of Flunarizine which is a difluorinated derivative of cinnarizine. It is a seletive calcium channel antagonist. By reducing excessive transmembrane influx of calcium Fluver prevents cellular calcium overlod. It does not interfere with normal cellular calcium homeostasis. Fluver also has some antihistaminic and sedative properties. It binds at an affinity of 99% to plasma protein.is the preparation of Atenolol. It is a synthetic, ß-selective (cardioselective) adrenoreceptor blocking agent without membrane stabilizing or intrinsic sympathomimetic activity.

No Data

Fluver is indicated for the following conditions -
• Prophylaxis of classic (with aura) or common (without aura) migraine.
• Symptomatic treatment of vestibular vertigo owing to a diagnosed functional disorder of the vestibular system.
• Symptomatic treatment of dizziness, tinnitus, vertigo and headache owing to cerebral ischemia.
• Symptomatic treatment of intermittent claudication, Raynaud's phenomenon, paresthesiae, cold extremities, nocturnal cramp and trophic disorders owing to ischemia of the limbs.
• As add-on therapy to existing anticonvulsant medication in the refractory seizures.

Route of administration: Fluver should be taken in oral route.

Migraine: The recommended dose of Fluver for migraine prophylaxis is 10 mg orally once daily in adults and 5-1 Omg once daily in children. If a patient responds satisfactorily to the starting dose and if a maintenance treatment is required, the dose of Fluver should be decreased so that each week the patient has 5 days of treatment at the same daily dose of Fluver and 2 successive drug free days. Even if the prophylactic treatment is successful and well tolerated it should be interrupted after 6 months and reinitiated only if migraine relapses.

Vertigo and peripheral vascular disease: For vertigo, peripheral vascular disease and refractory epilepsy, treatment with Fluver is started with 10mg dose at bedtime for patients younger than 65 years of age and with 5mg dose at bedtime for patients older than 65 years. For vertigo dosage should be increased up to 20mg three times daily and for refractory epilepsy it should be increased up to 100mg daily with the maintenance dose targeted to produce serum levels of 60 g/litre.

Patients with hepatic disease: Since flunarizine is primarily metabolized in the liver, dosage adjustment is required in hepatic insufficiency.

Pregnancy: The safely of flunarizine for use in pregnancy has not been established.

Lactation: No data is available on the excretion of flunarizine in human breast milk. Breast feeding should therefore be avoided in women taking flunarizine.

Discontinue therapy if fatigue increases progressively.

Drowsiness or fatigue, weight gain, increased appetite, depression and extra pyramidal symptoms may occur.

Flunarizine is contraindicated in patients with hypersensitivity to flunarizine or cinnarizine, depressive illness, Parkinson’s disease or extra pyramidal disorders.

Drug interaction with medication: Alcohol, hypnotics or tranquilizers may interact with flunarizine.

Drug interaction with food and others: Not applicable.

No Data

No Data

Store in a cool & dry place. Protect from light.

Fluver 5 mg tablet: Each tablet contains Flunarizine 5 mg as Hydrochloride BP.
Fluver 10 mg tablet: Each tablet contains Flunarizine 10 mg as Hydrochloride BP.

Storage
Store in a cool and dry place protected from light. Keep away from the reach of children.

Packing
Fluver 5 mg tablet: Carton of 100 tablets in blister.
Fluver 10 mg tablet: Carton of 100 tablets in blister.